[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chang et al., 2015 - Google Patents

Systematic review: cessation of long‐term nucleos (t) ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

Chang et al., 2015

Document ID
11320278732328847335
Author
Chang M
Liaw Y
Hadziyannis S
Publication year
Publication venue
Alimentary Pharmacology & Therapeutics

External Links

Snippet

Background It has been debated whether finite nucleos (t) ide analogue therapy is feasible in HB eAg‐negative chronic hepatitis B. Aim To review this issue systematically. Methods Using text terms HB sAg and various nucleos (t) ide analogues, PubMed was searched …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides

Similar Documents

Publication Publication Date Title
Chang et al. Systematic review: cessation of long‐term nucleos (t) ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B
Ghany et al. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad
Feld et al. Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
Gane et al. Efficacy and safety of prolonged 3‐year telbivudine treatment in patients with chronic hepatitis B
Fabrizi et al. Meta‐analysis: anti‐viral therapy of hepatitis B virus‐associated glomerulonephritis
Kuo et al. Chronic hepatitis B infection
Kim et al. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis
Chevaliez et al. Analysis of ribavirin mutagenicity in human hepatitis C virus infection
Pawlotsky Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures
Manolakopoulos et al. Long‐term therapy with adefovir dipivoxil in hepatitis B e antigen‐negative patients developing resistance to lamivudine
Mutimer et al. Management of HBV-and HCV-induced end stage liver disease
Su et al. Improving clinical outcomes of chronic hepatitis B virus infection
Hui et al. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon
Chen et al. Extended peginterferon alfa‐2a (Pegasys) therapy in Chinese patients with HBeAg‐negative chronic hepatitis B
Miyake et al. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
Cooksley Do we need to determine viral genotype in treating chronic hepatitis B?
De Clercq Current treatment of hepatitis B virus infections
Natsuizaka et al. Long‐term follow‐up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region
Reijnders et al. Relapse of chronic hepatitis B after discontinuation of nucleos (t) ide analogs: is the glass half full or half empty?
Wong et al. The safety of stopping nucleos (t) ide analogue treatment in patients with HBeAg‐negative chronic hepatitis B
Broquetas et al. Current perspectives on nucleos (t) ide analogue therapy for the long-term treatment of hepatitis B virus
Lai et al. Updates in the management of hepatitis B in children
Gallego et al. Evaluation of initial virological response to adefovir and development of adefovir‐resistant mutations in patients with chronic hepatitis B
Hadziyannis Update on hepatitis B virus infection: focus on treatment
Meng et al. Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010–2014)